FDA Approval

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A new 31-strain vaccine enters final trials, threatening to upend the market and offer unprecedented protection against a persistent bacterial threat.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.